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The complement system constitutes an effective first line of defense against invading pathogens. Its components recognize pathogenic cell surfaces and trigger cell lysis and inflamma-
tory responses1,2. Depending on the molecular recognition pattern, 
there are three distinct routes by which activation can be initiated: 
the classical, the lectin and the alternative pathways. These path-
ways converge at the proteolytic cleavage of the third component of 
complement, C3, generating the C3a and C3b activation fragments. 
C3b also participates in amplification of its own production via 
the positive-feedback loop of the alternative pathway (AP)2,3. It is 
subsequent to C3 activation that the major effector mechanisms of 
complement are expressed. These include C3-dependent opsoniza-
tion, important for phagocytic elimination, and generation of the 
membrane-attack complex (MAC), which leads to membrane dis-
ruption and cell lysis. Dysregulation of AP activity by genetic muta-
tions, neutralizing antibodies to complement regulatory proteins, 
or stabilizing antibodies to complement complexes predisposes 
individuals to diverse disorders including paroxysmal nocturnal 
hemoglobinuria (PNH), age-related macular degeneration (AMD), 
atypical hemolytic uremic syndrome (aHUS) and C3 glomerulo-
nephritis (C3G)4–7. While disease manifestation is often local, for 
example, in the kidney or in the eye, many of these diseases also 
display systemic overactivation of the pathway, and their effective 
treatment may require inhibition both systemically and locally.
Complement factor D (FD) is the rate-limiting enzyme of the AP, 
and it plays a key role in both AP-initiated C3 activation and subse-
quent amplification of this central activation step. FD cleaves factor 
B (FB) when it is complexed with C3b to generate an active C3 con-
vertase (C3bBb), cleaving C3 into C3a and C3b. C3b is deposited 
onto acceptor surfaces (opsonization). Recruitment of a further C3b 
molecule to the membrane-bound C3bBb complex generates a C5 
convertase, leading to C5a release and MAC (C5b to C9) formation 
on targeted surfaces with subsequent membrane disruption and 
cell lysis8. FD is a trypsin-like S1 serine protease (228 amino acids 
(aa), 24 kDa), which circulates in plasma in a mature, but latent, 
self-inhibited form. Full proteolytic activity of FD requires a con-
formational change upon binding to its surface-bound endogenous 
substrate C3bB9. Latent FD is characterized by an atypical active 
site architecture comprising the catalytic triad in an inactive con-
formation, a self-inhibitory loop (aa 214–218) restricting access to 
the non-prime recognition sites, and an Arg218–Asp189 salt bridge 
at the bottom of the S1 pocket10,11. The protease does not recognize 
peptide substrates, but it still exerts weak catalytic activity against 
synthetic lysine-derived thioesters12. Irreversible covalent FD 
inhibitors have been reported; however, lack of specificity toward 
multiple other S1 proteases prevents their clinical use13–15. While an 
antigen-binding fragment (Fab) capable of neutralizing FD activ-
ity is in clinical trials for the treatment of dry age-related macular 
degeneration (AMD), its use is limited to intravitreal injection16. No 
specific FD inhibitors are currently available for oral therapy of dis-
eases linked to AP dysregulation.
In this report, we describe the discovery of potent, selective and 
reversible small-molecule inhibitors of FD by use of a structure-
based design approach in combination with fragment-based screen-
ing. These inhibitors efficiently blocked AP activation in human 
whole blood, and their oral administration to FD-humanized 
C57Bl/6 mice inhibited lipopolysaccharide (LPS)-induced AP 
activation both systemically and in ocular tissues. Furthermore, 
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Complement is a key component of the innate immune system, recognizing pathogens and promoting their elimination. 
Complement component 3 (C3) is the central component of the system. Activation of C3 can be initiated by three distinct 
routes—the classical, the lectin and the alternative pathways—with the alternative pathway also acting as an amplification loop 
for the other two pathways. The protease factor D (FD) is essential for this amplification process, which, when dysregulated, 
predisposes individuals to diverse disorders including age-related macular degeneration and paroxysmal nocturnal hemoglo-
binuria (PNH). Here we describe the identification of potent and selective small-molecule inhibitors of FD. These inhibitors 
efficiently block alternative pathway (AP) activation and prevent both C3 deposition onto, and lysis of, PNH erythrocytes. Their 
oral administration inhibited lipopolysaccharide-induced AP activation in FD-humanized mice. These data demonstrate the 
feasibility of inhibiting the AP with small-molecule antagonists and support the development of FD inhibitors for the treatment 
of complement-mediated diseases. 
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FD inhibition prevented C3 deposition on, and lysis of, human 
erythrocytes in an assay that mimics lytic sensitivity of PNH eryth-
rocytes. These findings were confirmed with erythrocytes from 
PNH patients. Taken together, these data demonstrate the feasibility 
of inhibiting the AP with highly specific small-molecule antagonists 
of FD to treat complement-mediated diseases for which there are 
currently either no or sub-optimal therapies.
reSulTS
identification of small-molecule factor D inhibitors
Using multiple-hit-finding strategies, we set out to discover selec-
tive small molecules, with oral bioavailability, capable of blocking 
FD proteolytic activity. Two high-throughput screens, based on 
either FD thioesterolysis or on MAC formation, failed to deliver 
validated hits. We therefore applied a structure-based library design 
approach in combination with in silico docking of fragments. Use of 
a (S)-proline-based library was inspired by the co-crystal structure 
of compound 1 in complex with kallikrein-7 (KLK7), a related S1 
serine protease (Fig. 1a,b). Compound 1, which originated from a 
separate drug discovery effort, occupies the buried S1 pocket and 
extends into the prime site (S1′–S2′) with the catalytic His57 side 
chain in a displaced non-catalytic conformation. The orientation 
of KLK7-bound 1, forming several key hydrogen bond interac-
tions, suggested that this binding pose might be compatible with 
the topology of the latent FD active site10, thus providing us with an 
attractive opportunity for a FD-tailored inhibitor design.
A set of proline analogs of 1, bearing moieties that could reach 
into the S1 and S2′ pockets, was selected for synthesis based on 
docking (GLIDE17) of a virtual library to the crystal structure of FD 
(Supplementary Results, Supplementary Fig. 1a,b). Evaluation of 
these compounds for inhibition of FD proteolytic activity against a 
thioester-based substrate identified compound 2 (Fig. 1a), which 
showed a half-maximum inhibitory concentration (IC50) of 14 μM 
(Supplementary Table 1) and was equipotent against KLK7 (IC50 = 
9 μM). 1H–15N HSQC NMR spectroscopy18 was used to demonstrate 
direct binding of 2 to uniformly 15N-labeled FD (Supplementary 
Fig. 1c). We further developed an in vitro FD proteolytic assay to 
determine the inhibition of the formation of the factor B cleav-
age product Ba (Supplementary Fig. 2) using the cobra venom 
factor (CVF)–FB complex as a surrogate endogenous substrate19. 
Consistent with the biochemical and biophysical data, 2 inhibited 
FD proteolytic activity against the CVF–FB complex with an IC50 
value of 33 μM, confirming 2 as a viable starting point for further 
optimization.
The crystal structure of 2 in complex with FD (Fig. 1c) revealed 
key binding features consistent with our library design concept. The 
molecule binds in a bent conformation, penetrating deeply into the 
S1 pocket and occupying the S1′ and S2′ sites. The benzoate moiety 
is flanked by Gly216–Arg218 of the self-inhibitory loop and packs 
against the Cys191–Lys192 peptide bond, positioning the carboxy-
lic ester oxygen at a 3.4-Å distance to the nitrogen of Arg218 at the 
bottom of the S1 pocket. The urea spacer carbonyl is within binding 
distance to the NH of Gly193 forming part of the oxyanion hole. The 
His57 side chain adopts an outward conformation to accommodate 
the central proline scaffold in close proximity to the Cys42–Cys58 
disulfide bond, and the CF3O group of 2 is positioned in a small 
hydrophobic indentation of the S2′ binding site.
generation of potent and selective inhibitors
To discover alternative S1 binding structural motifs with improved 
affinity and on-target selectivity, we employed fragment-based 
screening20. Fragments are molecules of low molecular weight, typi-
cally well below 300 Da, and high solubility, rendering them suitable 
to bind to cryptic or transient pockets of protein surfaces. Because 
of their intrinsically lower complexity, they are much better suited 
than larger-sized ligands to sample the chemical space of a binding 
site21. Consequently, hits are generally more frequent in fragment-
based screening than in HTS campaigns, but they may bind only 
weakly to the biological target. This necessitates growing or com-
bining fragments with other structural motifs, such as compound 
2 in the case of FD, in order to generate compounds with higher 
affinity. Rather than screening random libraries of fragments, we 
chose a focused, structure-based approach and first selected a set 
of 52,000 fragments (molecular weight ≤ 350 Da; Supplementary 
Fig. 3a), docking them in silico into distinct FD active site confor-
mations based on the PDB 1DIC14 crystal structure. Screening of a 
diverse set of top-scoring fragments at 100 μM (nominal concen-
tration) by ligand-observation NMR (WaterLOGSY22) in the pres-
ence of FD identified 3 (Fig. 1a) as a hit. To ascertain binding and 
allow for quantification of binding affinity, we synthesized a more 
water-soluble carboxylic acid analog, 4 (Fig. 1a), which, in contrast 
to 3, showed concentration-dependent chemical shift changes in the 
1H–15N HSQC NMR spectrum (average NMR dissociation constant 
(Kd) = 1,600 μM; Supplementary Fig. 3b,c). The co-crystal struc-
ture of 4 bound to FD (1.46-Å resolution) showed the 2-carboxam-
ide indole positioned in S1 and flanked by the self-inhibitory loop 
and the Lys192 side chain (Fig. 1d). The deeply buried terminal 
carboxamide group is hydrogen bonded to the Arg218 guanidine 
and the Thr214 carbonyl of the S1 pocket, and the tethered benzoic 
acid moiety of 4 is exposed to the solvent space without making 
direct binding contacts to the protein.
The co-planar superposition of the S1 binding moiety of 4 with 
the ortho-benzoic ester portion of 2 (Fig. 1d) prompted us to merge 
both inhibitors. The design concept was supported by proline ana-
log 5 (IC50 = 5.8 μM, thioesterolysis assay; Fig. 2a), which was iden-
tified by a retrospective structure-similarity search in the Novartis 
compound collection and was predicted by computational model-
ing to bind with its N-methylindole portion to S1 in a similar over-
lapping pose (Fig. 2b). Combining a carboxamide group, as in 4, 
with an indole-like scaffold, as in 5, followed by further extensive 
chemical optimization in a number of iterative design cycles, led 
to the 6-aza-indazole 6 (Fig. 2a) as a highly potent and selective 
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Figure 1 | Structure-based evolution of reversible small-molecule human 
FD inhibitors. (a) Structure, binding affinities and in vitro potencies of 
compounds 1–4 determined by protein nMR and biochemical assays.  
(b) co-crystal structure of 1 (orange) in complex with KlK7. Hydrogen 
bonds to Gly193 and His41 are highlighted. the surface of the unoccupied 
S2 site is colored in yellow. (c) Ribbon diagram of the Fd active site in 
complex with 2 (orange) spanning S1–S2′. the self-inhibitory loop (pink)  
is in a closed, the His57 side chain in a non-catalytic ‘outward’ 
conformation. (d) Superposition of 2 (orange) and 4 (green) showing 
hydrogen bonds of the 4 carboxamide to Arg218/thr214. the 4 benzoate 
moiety is exposed to solvent.
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inhibitor of FD. In a direct binding assay using surface plasmon 
resonance (SPR) spectroscopy, 6 showed an average Kd of 0.006 μM 
(Fig. 2c,d; Supplementary Table 2), with a fast association of the 
protein–ligand complex (kon = 1.64 × 106 M−1s−1), and did not show 
binding to factor B, the second serine protease of the alternative 
pathway. Proteolytic cleavage of FB by FD in the biochemical assay 
was inhibited by 6 with an IC50 value of 0.03 μM (Fig. 2e).
Next we determined the ability of compound 6 to inhibit AP 
activation in a more physiological setting. The inhibitor effec-
tively blocked both AP-mediated hemolysis in 10% human serum 
(IC50 = 0.006 μM) and AP-induced MAC formation in lepirudin-
anticoagulated 50% human whole blood (IC50 = 0.14 μM; Fig. 2f). 
Moreover, 6 is highly selective for human FD, showing no inhibi-
tion of FB proteolytic activity (Supplementary Fig. 2c,d), no inhi-
bition of classical and lectin complement-pathway activation (see 
Online Methods), and no significant effects (up to 10 μM) in a 
broad assay panel of receptors, ion channels, kinases and proteases 
(Supplementary Table 1).
The crystal structure of 6 bound to FD confirmed the overall 
binding pose extending from S1 to S2′, with the self-inhibitory loop 
shielding the non-prime site and the catalytic His57 adopting a 
‘non-canonical’ catalytic-triad conformation (Fig. 2g). The termi-
nal carboxamide group of the ligand is in close binding contact to 
Arg218 and forms additional water-mediated hydrogen bonds with 
Ser190 and Ile227 in S1 and the backbone NH of Gly193 and  the 
carbonyl of Leu41. The meta-Cl substituent positioned in S2′ forms 
a halogen–carbonyl bond with Trp141; the ortho-F atom further 
strengthens this interaction.
Compound 6 selectively blocks factor D activity in vivo
Compound 6 demonstrated only modest inhibition of murine FD 
(IC50 = 0.86 μM). In order to understand the striking difference 
in human versus mouse IC50 values, we solved the crystal structure 
of murine FD at 1.25-Å resolution, which revealed that the self-
inhibitory loop (Trp215–Arg218) adopts a distinct conformation 
compared to the human protease23, with the carbonyl group of 
Gly216 preventing inhibitor binding to the narrower S1 pocket. 
A significant conformational movement of the murine FD self-
inhibitory loop would thus be required in order to accommodate 
inhibitor 6 in the S1 binding site (Fig. 3a).
In order to pursue in vivo pharmacology studies, we generated 
C57Bl/6 mice expressing only the human orthologous enzyme 
(human-FD knock-in (KI) mice) (Fig. 3b). The average human-FD 
blood level of female KI mice used for in vivo studies was 
0.78 μg/mL (Fig. 3c) and hence within the range reported for 
humans24. Reconstitution experiments with serum obtained from 
CFD−/− mice demonstrated that human FD effectively activates 
murine FB, as previously reported25. In line with the species selec-
tivity seen for inhibition of FD, which is a result of the different 
active site architectures, compound 6 blocked C3 cleavage only in 
the serum of mice expressing human FD, but not in serum of wild-
type mice (Fig. 3d). These results provide strong experimental evi-
dence that the inhibition of the alternative complement pathway in 
the presence of compound 6 is indeed target specific.
AMD patients commonly have genetic alterations in AP compo-
nents and evidence of systemic AP overactivity24,26–28 with pathology 
that manifests in retinal tissue. We sought to model systemic com-
plement activation in mice by injection of lipopolysaccharide (LPS). 
In human-FD KI mice we observed a dose- and time-dependent 
increase in AP activation after intraperitoneal (i.p.) injection of LPS, 
as indicated by rising levels of Ba and the C3 breakdown products 
C3d and iC3b in both plasma and ocular tissue (Supplementary 
Fig. 4). At the 7.5-h time point after LPS administration, levels of Ba 
or C3d/iC3b were ~2- to 3-fold of those in the control group. When 
administered by oral gavage 3.5 h after LPS, compound 6 dose-
dependently inhibited complement activation as determined 4 h 
post-dose in both plasma and ocular tissue, with full inhibition at 
10 mg/kg (Fig. 4a,b). Technical limitations do not allow clean sepa-
ration of retinal tissue from the eye vasculature, limiting the conclu-
sions that can be drawn with respect to local retinal complement 
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Figure 2 | identification and characterization of potent and selective human FD inhibitor 6. (a) chemical structures of 5 and 6. (b) computational model 
of 5 (yellow and pink sticks) in complex with Fd suggesting two distinct binding conformations of the indole portion within the S1 pocket. overlaid is the 
crystal structure of 4 (green sticks) in complex with Fd. (c) direct binding of 6 to immobilized Fd (blue) and Fb (red) determined by SpR spectroscopy. 
proteins were exposed (arrows) to increasing concentrations of 6 (single-cycle kinetics). Ru, response units. (d) binding of 6 to immobilized Fd by 
standard kinetics SpR. (e) ic50 determination (n = 4 experiments) for inhibition of Fd activity by 6 as indicated by formation of the Fb cleavage product ba, 
using cvF–Fb as substrate. (f) inhibition of Ap-mediated MAc formation by 6 in 50% whole blood from four individual donors. error bars denote s.d. of 
three technical replicates. Average ic50 value was 144 nM. (g) crystal structure of Fd-bound 6 spanning the S1–S2′ pockets. Self-inhibitory loop (pink) is in 
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inhibition and blood-retina barrier penetration of 6 in mice. To test 
the duration of action, a single 30 mg/kg oral dose of 6 was given to 
separate groups of mice at time points ranging from 4 to 24 h before 
study termination, while LPS (i.p.) was given 7.5 h before termina-
tion in all animals to maintain a consistent interval of LPS exposure 
(Supplementary Fig. 5). Compound 6 showed sustained inhibition 
of LPS-induced AP activation for at least 8 h post-dose with a half-
maximal efficacious concentration (EC50) of 0.034 μM (Fig. 4c,d).
Factor D inhibition prevents lysis of PNH erythrocytes
Importantly, compound 6 was active in an assay that mimics comple-
ment deposition onto, and hemolysis of, PNH erythrocytes (Fig. 5a 
and Supplementary Fig. 6). PNH is caused by a somatic mutation 
in the PIGA gene in hematopoietic stem cells, resulting in deficiency 
of glycosylphosphatidylinositol (GPI)-anchored complement regu-
lators CD55 and CD59 (ref. 5). To simulate the pathophysiology 
in vitro, normal human red blood cells (RBCs) were incubated with 
blocking antibodies against CD55 and CD59, and the AP was acti-
vated by serum acidification29. Compound 6 inhibited both hemo-
lysis and C3 deposition on the surface of RBCs with an IC50 value of 
0.07 μM, consistent with inhibition of the AP amplification loop. In 
contrast, the anti-C5 monoclonal antibody eculizumab, the current 
standard of care for PNH30, blocked hemolysis but generated eryth-
rocytes that were extensively coated with C3 fragments (Fig. 5a and 
Supplementary Fig. 6). Such C3-fragment-coated RBCs are com-
monly observed in eculizumab-treated PNH patients31 and are sus-
ceptible to extravascular hemolysis in the spleen and liver. This C3 
coating provides a plausible explanation for the finding that ~40% 
of eculizumab-treated patients remain transfusion dependent29. 
Furthermore, using erythrocytes from PNH patients, we examined 
the ex vivo efficacy of the structurally related compound 7 (Fig. 5b), 
which has similar in vitro potency to compound 6 (Supplementary 
Table 1; IC50 = 0.05 μM in the AP-induced MAC formation assay 
using 50% human whole blood), but showed higher permeability 
and no efflux in Caco-2 cells32 (Papp (A-B) × 10−6 (cm/s) = 15.3; 
Papp (B-A) × 10−6 (cm/s) = 18.1; (B-A)/(A-B) = 1.19; respective values 
for compound  6: 1.35, 9.66 and 7.17) and improved oral bioavail-
ability (F = 100%) in rat (Supplementary Table 4; for compound 6: 
F = 28%). In line with its activity in the surrogate PNH assay, 
compound 7 fully blocked C3 deposition on the surface of CD59-
negative PNH erythrocytes and prevented their lysis (Fig. 5a,c,d). 
Targeting the AP amplification loop in PNH therefore has the poten-
tial advantage over anti-C5 therapy of blocking not only extravascu-
lar hemolysis, but also any C3-driven pathology.
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the level in pos is indicated by the lines labeled lpS. n = 4 mice per group. 
data shown as mean ± s.e.m. in a–c; *P < 0.05, **P < 0.01, ***P < 0.001 
compared to positive control in a–c by AnovA with dunnett’s post test. 
(d) terminal concentration of 6 in each sample from dose–response and 
duration-of-action studies (n = 62), relative to plasma ba inhibition, was 
used to calculate ec50 = 0.034 μM for 6. dashed lines represent the 95% 
confidence band. data points on graph are color coded to time (h) after 
compound administration.
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DiSCuSSioN
The non-canonical active site architecture of latent factor D, char-
acterized by a distorted conformation of the catalytic triad and a 
self-inhibitory loop that prevents access to the non-prime sites, ren-
ders this enzyme of the S1 protease family a challenging target for 
drug discovery. This is reflected by the fact that we did not find 
any suitable inhibitor by high-throughput screening of a 1.2 million 
compound collection. The work described here demonstrates the 
utility of structure-based focused screening and rational drug design 
coupled with a chemical library approach to discover potent, selec-
tive and reversible small-molecule inhibitors of FD. Central to the 
optimization of the initial inhibitors was the subsequent dedicated 
screening of an in silico–selected target-focused fragment library, 
which, in combination with a detailed structural understanding of 
the binding modes of the various compounds, allowed the combi-
nation of different structural motifs and ultimately led to the final 
inhibitors. Although an Fab fragment capable of neutralizing FD 
catalytic activity is currently in clinical trials for the treatment of 
geographic atrophy, its use is restricted to local injection. In addi-
tion to the inherent short half-life of Fab fragments, the steady-state 
level of endogenous FD, the result of a high production rate coupled 
with rapid renal clearance, is unfavorably disturbed by systemic 
application of a FD antibody or antibody fragment16. Therefore, our 
small-molecule compounds are the first inhibitors that would allow 
sustained inhibition of FD at a systemic level.
Significant species specificity for human versus mouse FD was 
observed for this inhibitor chemotype. This can be rationalized by 
the distinct active site conformations of murine and human FD as 
revealed by X-ray crystallography. Consequently, compound 6 did 
not block AP activation in the serum of wild-type C57Bl/6 mice, and 
we had to generate human-FD KI mice to demonstrate AP inhibition 
in vivo. Based on these findings, as well as on the compound’s favor-
able biochemical profile in terms of potency and selectivity, we con-
clude that the in vivo and ex vivo effects observed with our inhibitors 
are in fact the result of selectively blocking FD proteolytic activity.
Inhibitors 6 and 7 were active in an assay that mimics PNH 
pathophysiology. Both compounds not only blocked AP-induced hemo-
lysis but also inhibited C3 opsonization of erythrocytes. Additionally, 
compound 7 was found to prevent both lysis and opsonization of 
erythrocytes from PNH patients. Opsonizing C3 fragments are recog-
nized by complement receptors 1, 3 and 4 expressed on phagocytes and 
Kupffer cells, rendering C3-coated erythrocytes subject to destruction by 
extravascular hemolysis in the liver and spleen. Extravascular hemoly-
sis often becomes more apparent in patients receiving anti-C5 therapy, 
which prevents MAC-mediated intravascular lysis but does not block C3 
deposition on erythrocytes31. Inhibition of FD may therefore offer a ther-
apeutic advantage over the current standard of care in PNH treatment. In 
addition, systemic dysregulation of the AP consequent to genetic muta-
tions in its constituent proteins, or auto-antibodies stabilizing the C3 
convertase (either directly or by neutralization of complement regulatory 
proteins), predisposes to a number of diseases with local manifestation in 
organs such as the kidney. Fully effective treatment of these diseases may 
require AP inhibition at a systemic level, and our findings support the 
potential clinical utility of oral FD inhibitors for such use.
Genetic deficiency of AP components is associated with increased 
susceptibility to bacterial infection33. It will therefore be important 
to evaluate the clinical safety of FD inhibitors, not just for on-target 
and off-target risks traditionally associated with drug discovery, 
but also for infection risk. In this context it is possible that specific 
alternative-pathway blockade, when compared to C5 blockade, may 
carry a reduced risk for infections such as Neisseria meningitidis, for 
which the lytic pathway is critically important for bacterial elimina-
tion. This will be particularly true if patients are adequately vacci-
nated and can therefore recruit the lytic pathway through efficient 
antibody-dependent classical pathway activation. In addition, the 
use of small-molecule inhibitors would, in principle, allow more 
tunable pharmacologic intervention than that with antibody-based 
therapies. This may be important for diseases where AP activation 
is the result of an imbalance between stimulatory and regulatory 
mechanisms, for example, due to genetic polymorphisms (AMD) or 
somatic mutations (PNH), where the therapeutic objective would 
be to convert the patient’s status from high-risk to low-risk pheno-
type. If feasible, this would permit better titration for the desired 
therapeutic effect versus any potential side effects.
The work presented here offers a new way to target the alterna-
tive pathway in the treatment of complement-related diseases. The 
next logical step in their development will be to define the clinical 
safety profile of FD inhibitors, and to evaluate this, on an indica-
tion-specific basis, against the exciting prospect for their significant 
therapeutic benefit. 
received 20 May 2016; accepted 15 august 2016; 
published online 24 October 2016
meTHoDS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Atomic coordinates and structure factors for the 
human KLK7–1 complex, for human FD in complex with com-
pounds 2, 4 and 6, and for the mouse apo-FD are deposited in the 
Protein Data Bank with accession codes 5FAH, 5FBE, 5FBI, 5FCK 
and 5FCR, respectively.
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Figure 5 | inhibitors of FD prevent C3 deposition on and hemolysis of 
PNH erythrocytes. (a) dose–response curves for inhibition of hemolysis 
of erythrocytes from healthy donors for compound 6, compound 7, and 
eculizumab (see online Methods and Supplementary Fig. 6). erythrocytes 
were incubated with cd55/cd59 blocking antibodies and transferred 
into acidified serum in the presence of Mg2+–eGtA to limit activation to 
the alternative pathway and prevent antibody-mediated activation of the 
classical pathway. Hemolysis was measured by increase in optical density. 
curves are representatives of n = 11 (compound 6), n = 2 (compound 7) 
and n = 7 (eculizumab) measurements. (b) Structure of compound 7.  
(c) compound  7 (1 μM) blocks hemolysis of cd59-negative erythrocytes 
from a pnH patient. c3 deposition was assessed using a c3 polyclonal 
antibody. number of Rbcs in each quadrant is indicated. Heat inactivation 
neutralizes serum complement activity. note that lysed cd59-negative 
pnH erythrocytes disappear from the gate in the absence of inhibitor, and 
no c3 deposition could be detected. (d) inhibition of hemolysis of pnH 
erythrocytes. blood from 3 patients was analyzed in 2–14 repeats; mean 
± s.e.m. is shown. compound 7 was used at 1 μM. Hemolysis of pnH 
erythrocytes was determined by flow cytometry (see online Methods).
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oNliNe meTHoDS
Materials. Cobra venom factor (CVF) was purchased from Quidel. Anti-Ba 
neoepitope IgGs have been raised in rabbit and were purified from serum 
(Eurogentec). Anti-C3a neoepitope antibodies were purchased from Hycult. 
The thiol-scavenging reagent 2,4-dinitrobenzenesulfonyl-2,7-desmethyl- 
fluorecein was prepared according to the published protocol34. Anti C9 
neoepitope antibody (clone aE11) conjugated to alkaline phosphatase for detec-
tion of MAC deposition was custom ordered from Diatec Monoclonals AS. 
Zymosan A was obtained from Sigma (Z-4250). Anti-mouse C3b/iC3b/C3c 
(Hycult biotech; HM1065) was obtained from Hycult Biotech and Goat anti-rat 
IgG HRP-conjugated Antibody from Southern Biotech (3010-05). Anti-CD55 
clone HD1A (mIgG2b) was kindly provided by P. Morgan, University of Cardiff, 
UK35. Anti-CD59 clone MEM43 (mIgG2a) was purchased from ABCAM, anti-
C3d (neo) mIgG1 from Quidel (A250) and anti-C5b-9 (C9 neoepitope, clone 
aE11; mIgG2a) from Life Technologies. Antibodies were pre-labeled using 
Zenon Alexa Fluor 488 mouse IgG1 or Zenon Alexa Fluor 647 mouse IgG2a 
Labeling Kit obtained from Life Technologies. FITC-conjugated anti-C3 poly-
clonal antibody was obtained from Abcam (Ab14396) and PE-conjugated 
anti-CD59 monoclonal antibody from Valter Occhiena (59-PE). The anti-C5 
monoclonal antibody eculizumab (Soliris) was obtained from a US Pharmacy. 
All other chemicals were of analytical grade. For western blot detection of mouse 
Ba and C3d+iC3b, a polyclonal anti-human factor B (Quidel, A311) and poly-
clonal anti-mouse C3d (R&D Systems; AF2655) were used. Human factor D was 
detected using goat polyclonal anti-human antibody (R&D Systems; AF1824).
Preparation of recombinant murine and human FD catalytic domains. Mouse 
Cfd (UniProt; P03953) catalytic domain (G24–T253) was amplified by RT-PCR 
from C57Bl/6 RNA (lung), whereas human CFD (UniProt; P00746) catalytic 
domain (G24-A253) was amplified by PCR using an in-house cDNA collec-
tion. The PCR products were cloned into pET24 (Novagen) and expressed in 
Escherichia coli (Rosetta) in the form of inclusion bodies. Inclusion bodies were 
solubilized in 6 M guadinium HCl containing 100 mM DTT to reach a protein 
concentration of approximately 5 to 10 mg/mL. Pro-FD refolding was obtained 
by rapid dilution of solubilized inclusion bodies at 10 °C with 50 mM Tris/HCl 
(pH 8.5) containing 0.8 M arginine, 10 mM CaCl2, 1 mM EDTA, 1 mM GSH, 
and 0.5 mM glutathione disulfide (GSSG), leading to a final protein concentra-
tion of 50 μg/mL. After gentle agitation at 10 °C for one day, the protein was 
concentrated and purified by size-exclusion chromatography (SEC). FD cata-
lytic domain was formed by removal of the pro-petide sequence in the pres-
ence of trypsin-coated beads for 6 h at 8 °C. For the analogous preparation of 
uniformly 15N-isotope-labeled human FD, an M9 minimal medium with [15N]
H4Cl as the sole nitrogen source was used.
Preparation of recombinant human complement FB. The catalytic domain 
(Asp470–Leu764) of human CFB (UniProt; P00751) was amplified by PCR 
using an in-house cDNA collection. The PCR product was cloned into pMT–BIP 
and expressed in Drosophila SL3 cells that were grown in Sf-900 II medium 
containing 1% FCS (Invitrogen) as stable cell-line pools. Catalytic domain FB 
protein was purified from the cell culture medium by ultrafiltration and SEC.
Preparation of recombinant human KLK7 (Y180R mutant). Human KLK7 
(aa 37–253) (UniProt; P49862) was amplified by PCR using an in-house cDNA 
collection. To prevent autocleavage of KLK7, residue Tyr180 was replaced by 
Arg. The PCR products were cloned into a modified pET-24 vector (Novagen) 
directly after the N-terminal extension comprising His-tag, pro-peptide and 
enterokinase cleavage site. KLK7 was expressed in Escherichia coli BL21(DE3) 
in the form of inclusion bodies and was refolded by rapid dilution of solu-
bilized inclusion bodies at 10 °C with 50 mM Tris/HCl pH 8.0 buffer (10 °C 
cold) containing 2 M urea, 500 mM NaCl, 10 mM CaCl2, 0.1 M NH4Cl, 1 mM 
EDTA, 1.25 mM GSH and 0.5 mM GSSG at a final protein concentration of 
50 μg/mL. Refolded protein was purified using ion exchange chromatography 
(Q Sepharose), followed by an enterokinase cleavage step and final SEC.
Human KLK7 fluorescence-lifetime assay. Recombinant human KLK7 
(5 nM concentration) was pre-incubated with inhibitor at various concentra-
tions for 1 h at room temperature in 50 mM sodium citrate buffer at pH 5.6, 
containing 150 mM NaCl and 0.05% (w/v) CHAPS. The enzyme reaction was 
initiated by addition of the substrate Ac-Glu-Phe-Lys-Pro-Ile-Leu-Trp-Arg-
Leu-Gly-Cys(PT14)-Glu-NH2 (0.8 μM; Biosyntan, Berlin, Germany, product 
BS-#7599). Fluorescence-lifetime measurements were conducted on an Ultra 
Evolution fluorescence lifetime reader (TECAN, Männedorf, Switzerland). 
The excitation light source was a semiconductor laser at 405 nm, produc-
ing picosecond light pulses with a selected repetition frequency of 10 MHz. 
The emission was collected through a 450 nm bandpass filter with 25 nm 
bandwidth. The measurement time per well was set to 1 s, yielding approxi-
mately 1,000 counts in the peak channel. The parameters used as assay 
readout were the mono-exponential lifetimes. IC50 values were calculated from 
the plot of percentage of inhibition vs. inhibitor concentration using nonlinear 
regression analysis.
Complement FD thioesterolysis assay. The FD thioesterolysis assay was per-
formed according to published procedures12. Briefly, recombinant human 
or murine FD catalytic domain (10 nM concentration) were incubated with 
compound at various concentrations for 1 h at room temperature in 0.1 M 
Hepes buffer (pH 7.5) containing 1 mM MgCl2, 1 M NaCl and 0.05% CHAPS. 
The substrate Z-Lys-thiobenzyl (Bachem, Bubendorf, Switzerland) and 
2,4-dinitrobenzenesulfonyl-2,7-desmethyl-fluorecein were added to final 
concentrations of 200 μM and 25 μM, respectively. The increase in fluores-
cence was recorded at an excitation wavelength of 485 nm and an emission 
wavelength of 535 nm in a microplate spectrofluorimeter. IC50 values were 
calculated from percentage of inhibition of FD activity as a function of 
inhibitor concentration.
Human FD proteolysis assay (ELISA Ba). Recombinant human FD (10 nM 
concentration) was incubated with compound at various concentrations for 
1 h at room temperature in 0.1 M PBS (pH 7.4) containing 7.5 mM MgCl2 and 
0.075% (w/v) CHAPS. The preformed CVF–human-FB-substrate complex was 
added to a final concentration of 200 nM. After 1 h incubation time at room 
temperature, the enzyme reaction was stopped by addition of a 0.1 M Na2CO3 
buffer solution (pH 9.0) containing 0.15 M NaCl and 40 mM EDTA. Generation 
of Ba as the enzymatic cleavage product was quantified by an enzyme- 
linked-immunosorbent assay (ELISA). Aliquots of reaction samples were 
pipetted into 384-well high-capacity protein-binding plates (NUNC MaxiSorp) 
pre-filled with 96 μL/well of coating buffer. After an overnight incubation at 
4 °C, assay plates were washed with PBS–Tween 20. Remaining free binding 
capacity was saturated by the addition of Starting Block T20 for 5 min at room 
temperature, and assay plates were then washed with PBS–Tween 20. Anti 
Ba neoepitope antibody was added to each well, followed by incubation for 
60 min at room temperature and removal of excess antibody by washing with 
PBS–Tween 20. Then, goat anti-rabbit antibody labeled with HRP (172-1019; 
Bio-Rad) (1 μg/well in PBS–Tween 20) was incubated for 60 min at room tem-
perature as in the former step, and excess antibodies was removed by exten-
sive washing with PBS–Tween 20. HRP activity was measured after 20 min 
incubation time with QuantaBlu fluorogenic peroxidase substrate (100 μL) at 
room temperature. IC50 values were calculated from percentage of inhibition of 
FD activity as a function of test compound concentration.
Human FB proteolysis assay (ELISA C3a). Human CVF–Bb complex (3 nM 
concentration) was incubated with compound at various concentrations for 
1 h at room temperature in PBS at pH 7.4, containing 10 mM MgCl2 and 
0.05% (w/v) CHAPS. The enzyme reaction was started by addition of C3 diluted 
in the assay buffer to a final concentration of 1 μM. After 1 h incubation time at 
room temperature, the enzyme reaction was stopped by addition of an excess 
of various enzyme inhibitors (Roche, cOmplete Inhibitor Tablets). Generation 
of C3a as the enzymatic cleavage product was quantified by an enzyme-linked 
immunosorbent assay (ELISA). Aliquots of reaction samples were pipetted into 
384-well high-capacity protein-binding plates (NUNC MaxiSorp) pre-filled 
with 97 μL/well of coating buffer. After an overnight incubation at 4 °C, assay 
plates were washed with PBS–Tween 20. Remaining free binding capacity was 
saturated by the addition of Starting Block T20 for 5 min at room temperature, 
and assay plates were then washed with PBS–Tween 20. Anti-C3a neoepitope 
antibody was added to each well, followed by incubation for 60 min at room 
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temperature and removal of excess antibody by washing with PBS–Tween 20. 
Then, goat anti-mouse antibody labeled with HRP (A0168; Sigma) (0.2 μg/well 
in PBS–Tween 20) was incubated for 60 min at room temperaure as in the 
former step, and excess antibody was removed by extensive washing with 
PBS–Tween 20. HRP activity was measured after 20 min incubation time with 
Quantablu fluorogenic peroxidase substrate (100 μL) at room temperature. 
IC50 values were calculated from percentage of inhibition of FD activity as a 
function of test compound concentration.
Membrane-attack complex (MAC) formation assay in 50% human WB. 
Whole blood (WB) from individual donors was collected under the Novartis 
employee blood donor program, with informed consent from all participants. 
Blood was anticoagulated with the thrombin-specific anticoagulant lepirudin 
(Refludan, Bayer), then diluted in an equal volume of gelatin veronal buffer 
(GVB; Boston BioProducts) containing 2 mM MgCl2 and 10 mM EGTA (final 
concentration) for AP activation. Compound serial dilutions were prepared 
in DMSO, and the 50% WB mixture was pre-incubated with compound for 
15 min (final DMSO concentration in all test wells was 0.9%). Zymosan 
(Sigma) suspension at a final concentration of 1 mg/mL was added to all 
samples to initiate AP activation, which was allowed to proceed at 37 °C for 
40 min. Complement activation was stopped by adding an equal volume of 
0.05 M EDTA (final concentration of 25 mM). MAC generation was detected 
by coating the reaction supernatants onto a 384-well ELISA plate (Nunc 
Maxisorp). The plate was washed, then incubated with an alkaline phos-
phatase-conjugated mouse anti-human C9 neoepitope monoclonal antibody 
(clone aE11, Diatec) at 0.25 μg/mL. After washing, 4-methylumbelliferyl phos-
phate (4-MUP; Fisher) at 0.18 mg/mL in 0.1 M Tris/HCl (pH 9.0) containing 
2 mM MgCl2 was added and the plate was developed for 30 min. The reac-
tion was stopped with an equal volume of 0.2 M EDTA. Plates were read at 
355 nm excitation and 460 nm wavelength emission in an appropriate fluor-
ometer. Percentage of inhibition of complement deposition by the compound 
was calculated relative to the positive control (50% WB with assay buffer) after 
subtracting the background signal (50% WB with 25 mM EDTA added) to 
calculate the IC50 value using GraphPad Prism software.
Classical and lectin pathway MAC deposition assays. Black MaxiSorp (Life 
Technologies) plates were coated with human IgM (AbD Serotec) diluted to 
10 μg/mL in carbonate buffer (pH 9.5; Sigma) for the classical pathway, or 
mannan (from Saccharomyces cerevisiae; Sigma) diluted to 20 μg/mL in car-
bonate buffer (pH 9.5) for the lectin pathway assay. Compounds were serially 
diluted in DMSO in polypropylene V-bottom plates. Normal human serum 
(Quidel) was diluted to 1% in GVB++ buffer (Boston BioProducts) for the 
classical, or to 50% in GVB buffer (Boston BioProducts) supplemented to 0.5 
mM MgCl2 and 2 mM CaCl2 final concentrations for the lectin pathway assay. 
Diluted serum was added to the polypropylene plate with compound followed 
by pre-incubation for 15 min at room temperature and transfer of the mix-
ture to the coated reaction plate. The reaction plate was incubated at 37 °C for 
30 min to allow complement activation. The reaction was terminated by wash-
ing. MAC formation was detected with an alkaline-phosphatase-conjugated 
mouse anti-human C9 neoepitope monoclonal antibody (clone aE11, Diatec) 
at 0.25 μg/mL. After washing, substrate 4-MUP (Fisher) at 0.18 mg/mL in 
0.1 M Tris/HCl (pH 9.0) containing 2 mM MgCl2 was added and the plate 
was incubated for 30 min. Plates were read at 355 nm excitation and 460 nm 
emission wavelengths on a suitable fluorometer. Percentage inhibition of com-
plement deposition was determined in a similar manner as described above 
for the 50% human WB assay.
Complement alternate pathway hemolytic assay. Rabbit erythrocytes (Lampire 
Biological) were washed in cold PBS and resuspended at 8 × 107/mL in GVB 
buffer (Boston BioProducts) containing 5 mM MgCl2 and 10 mM EGTA. 
Resuspended erythrocytes (2.5 × 106 cells/well) were combined with 10% (final 
concentration) normal human serum (Quidel) containing various dilutions of 
compound in GVB buffer (plus 1% DMSO final concentration) and incubated 
for 1 h at 37 °C. A 0.1% NP40 (Sigma) solution in GVB was used as the 100% 
lysis control and GVB containing 1% DMSO was used as the vehicle control 
in this assay. The reaction mixture was centrifuged and the supernatant was 
removed to a new plate. Optical density was measured at 415 nm wavelength 
and percent hemolysis was calculated as: (OD sample − OD vehicle)/(OD 100% 
lysis − OD vehicle) × 100%.
Mouse C3 cleavage assay. Compound was titrated into serum obtained from 
wild-type C57Bl/6 or human FD knock-in C57Bl/6 mice and diluted to 50% 
by addition of gelatin buffer (0.15 mM CaCl2, 141 mM NaCl, 4.5 mM MgCl2, 
0.1% gelatin, 20 mM EGTA, 4.2 mM Hepes, pH = 7.3–7.4). Maximal C3 depo-
sition was determined in the absence of compound, and background activ-
ity was determined by replacing EGTA with EDTA. After pre-incubation for 
30 min at room temperature, 25 uL of serum was added to zymosan-coated 
plates and incubated for 40 min at room temperature. After washing, C3 depo-
sition was determined by ELISA by using rat anti-mouse C3b/iC3b/C3c anti-
body in the first step (1 h at 37 °C), followed by HRP-conjugated goat anti-rat 
IgG (45 min at room temperature) and addition of QuantaBlu (Pierce; #15169). 
Inhibition was calculated as (OD sample − OD background)/(OD max − OD 
background) × 100. Data was analyzed using GraphPad Prism, and the IC50 
value was determined using variable slope (four parameters) curve fitting.
Crystallography. KLK7 in complex with 1 was co-crystallized by the hang-
ing-drop vapor-diffusion method. A volume of 0.5 μL KLK7 solution in the 
presence of inhibitor 1 (24.6 mg/mL KLK7, 50 mM sodium acetate pH 5.6, 
100 mM sodium chloride, 2 mM compound 1, 1.8% DMSO) was mixed with 
0.5 μL reservoir solution (35% PEG 3350, 200 mM CaCl2, 100 mM sodium 
acetate pH 4.8) and equilibrated against 1 mL reservoir solution. For X-ray data 
collection, crystals were flash-frozen in liquid nitrogen. X-ray diffraction data 
were collected from a single crystal at the Swiss Light Source, beamline X10SA, 
equipped with a MAR 225 CCD detector. The diffraction data were proc-
essed and scaled with DENZO and SCALEPACK36, respectively. The structure 
was solved by molecular replacement using the program MOLREP37 and the 
coordinates of PDB code 1SPJ as a search model.
Human FD was crystallized by the hanging-drop vapor-diffusion method. 
A 1 μL FD solution (18–18.3 mg/mL FD, 10 mM Tris pH 7.0, 100 mM NaCl) 
was mixed with 1 μL reservoir solution (22% PEG 3350, 100 mM HEPES 
pH 7.5 or 25% PEG 3350, 100 mM Tris pH 8.0) and equilibrated against 1 
mL reservoir solution. Crystals were soaked by the addition of 0.5 μL inhibi-
tor stock solution (100 mM in 90% DMSO for  4 and  6, and 10 mM in 90% 
DMSO for 2) to the crystal containing drops for 45 min (2 h for compound 6) 
and flash-frozen in liquid nitrogen after addition of glycerol as cryoprotect-
ant. X-ray diffraction data were collected from single crystals at the Swiss 
Light Source, beamline X10SA, equipped with a MAR 225 CCD detector for 
crystals of FD in complex with 2 and 4, and a Rigaku FRE rotating anode 
equipped with a Saturn 92 CCD detector for a crystal of FD in complex with 6. 
The diffraction data were processed and scaled with XDS and XSCALE38, 
respectively. The structures were solved by molecular replacement using the 
program MOLREP and the coordinates of PDB code 1BIO as search model. 
Structures were built using the program COOT39 and refined using the pro-
grams Refmac40 and BUSTER41. Mouse FD was crystallized by the sitting-drop 
vapor-diffusion method. A 1 μL FD solution (14.4 mg/mL FD, 50 mM Tris 
pH 8.0, 100 mM NaCl) was mixed with 1 μL reservoir solution (0.1 M HEPES 
pH 7.0, 30% v/v Jeffamine ED-2001 pH 7.0) and equilibrated against 200 μL 
reservoir solution. Crystals were cryo-cooled in the reservoir solution with 
10% (v/v) added glycerol. All data collection and refinement statistics are sum-
marized in Supplementary Table 3. Images were generated using the program 
PyMOL (http://www.pymol.org)42.
NMR spectroscopy. A Bruker Avance II 500 MHz and Avance III HD 800 MHz 
spectrometer equipped with a cryogenically cooled probe head was used. 
1H–15N HSQC were recorded at 310 K using flip-back pulses43 and a watergate44,45 
sequence for water suppression. The NMR samples contained 100 μM uni-
formly 15N-labeled FD, 50 mM Tris–D11 (Cambridge Isotope Laboratories 
(CIL), 98% DLM-1814-5), 100 mM NaCl (Fluka catalogue nr. 71376), and 
10% D2O (CIL DLM-2259-1). Compound stock solution was prepared in 90% 
DMSO-D6/10% D2O (v/v) (DMSO-D6: Eurisotop, St. Aubin Cedex, France, cat. 
nr. D010ES). The concentration of compounds in buffer was determined by 
integration of the aromatic 1H signals and referencing to the internal standard 
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NH of Gly193 (referred to as the ‘oxyanion hole’; Fig. 1b). Ligand docking and 
scoring was performed with GLIDE by defining the formation of at least one 
hydrogen bond interaction of ligands in their docking pose, either with the NH 
of Gly193 and/or the carbonyl of Leu41, as a constraint. Visual inspection of 
the top-scoring compounds led to the selection of 12 structural motifs filling 
the S1 pocket and 4 residues suitably positioned in the S2′ pocket of FD. A total 
of 20 proline-based analogs (out of 48 possible combinations) were synthesized 
using a similar synthesis protocol as described for compound  2, followed by 
compound testing in the FD thioesterolysis assay.
Computational methods: Generation of a focused fragment library for NMR 
screening by WaterLOGSY. A set of some 52,000 fragments was assembled 
from the Novartis compound collection by applying a set of filter criteria 
for molecular properties including molecular weight, number of hydrogen 
bond acceptor/donor groups and rotatable bond (Supplementary Fig. 2). 
Compounds were docked using GLIDE into the ligand-free active site con-
formation of FD, which was adapted from the 1DIC PDB crystal structure 
as described above, and in which Asp189 forms a salt bridge with Arg218 at 
the bottom of the S1 pocket. Furthermore, a computational model of a more- 
open FD active site S1 conformation was constructed manually by accounting 
for FD to specifically recognize an arginine residue at the P1 cleavage site of the 
FB substrate. The Arg218 side chain was manually displaced from its crystal-
lographic location and was moved to an outward position, allowing the Asp189 
to make direct contact with fragments that were potentially binding into 
the S1 pocket. The same fragment library was then docked with GLIDE into 
the open protein conformation. The top-scored fragments identified from the 
two independent docking experiments were visually inspected, clustered 
according to the type of interactions with the protein (for example, ionic 
charge–charge, hydrogen bonding, dipole–dipole, others), and representa-
tives from each cluster were finally selected (225 fragments in total) for NMR 
screening by WaterLOGSY.
Generation of humanized complement FD knock-in mice (B6–Cfdtm1.1(CFD)Npa 
mice). The mouse Cfd genomic sequence containing the promoter, exon 1, 
intron 1, and 5 nucleotides from exon 2 was amplified by polymerase chain 
reaction (PCR) from C57Bl/6 mouse genomic DNA (Ensembl gene ID 
ENSMUSG00000061780) and was fused to the human CFD cDNA followed by 
the mouse Cfd 3′ UTR containing a stop codon as well as a poly-adenylation 
signal. The resulting mouse–human chimeric fragment was subcloned into 
the vector pRAY-2 containing a floxed neomycin resistance cassette (GenBank 
accession number U63120) followed by subsequent cloning of a PCR-amplified 
3′ homology fragment downstream of neomycin, resulting in the complement 
FD targeting vector. C57Bl/6 mouse embryonic stem (ES) cells were transfected 
by electroporation of ScaI-linearized FD targeting vector. Transfected ES cells 
were selected for neomycin resistance using 0.2 mg/ml geneticin (Invitrogen; 
#10131-019). Ten days after transfection, 300 G418-resistant ES cell clones were 
isolated and genotyped by PCR for homologous recombination with the primers 
CTATCGCCTTCTTGACGA and CCACCAGCCTGCGTATGT. Homologous 
recombination was confirmed by Southern blot and a positive targeted C57Bl/6 
ES cell clone was used for injection into BALB/C host blastocysts, which were 
then transferred into pseudopregnant CB6F1 foster females. Chimeric males 
were crossed with C57Bl/6 females and black offspring were genotyped. 
Removal of the floxed neomycin resistance cassette was done by crossing 
the mice with a Cre-recombinase-expressing line48,49 and resulted in mouse 
strain B6–Cfdtm1.1(CFD)Npa, named according to the International Committee 
on Standardized Genetic Nomenclature for Mice. Primers used for the geno-
typing of the humanized FD mice were CCTACCCTCCTCAGCAGCAC and 
CCAGGAGAACCTGCACCTTC.
Surrogate PNH human erythrocyte assay. Serum and heparinized blood 
from healthy volunteers were provided under informed consent and collected 
through the Novartis Tissue Donor Program (TRI0128) in accordance with the 
Swiss Human Research Act and with approval of the responsible ethic commit-
tee (Ethikkommission Nordwest- und Zentralschweiz). Serum was prepared by 
addition of Mg2+–EGTA (8 mM EGTA and 2.85 mM MgCl2 final concentration) 
to prevent antibody-mediated activation of the classical complement pathway, 
DSS (sodium 2,2-dimethyl-2-silapentane-5-sulfonate, CAS (2039-96-5), 
Cambridge Isotope Laboratories; DLM-32). One-dimensional 1H NMR data 
were acquired using excitation sculpting for water suppression46. Dissociation 
constants were calculated by assuming the formation of a 1:1 complex and by 
fitting the chemical shift to the equation: 
Δ Δd d= + + − + + −bound free d d- .(( ) (( ) ) )/( )P L K P L K P L P2 4 20 5
Where P is the protein concentration, L is the ligand concentration and Δδbound-free 
is the chemical shift difference between the bound and free protein (in parts 
per million, p.p.m.). Data fitting was accomplished according to a published 
protocol (R Core Team. R: A Language and Environment for Statistical 
Computing. (2014); http://www.r-project.org). Screening of a selected set of 
small molecules for their potential interaction with latent human FD was con-
ducted by WaterLOGSY at 10 μM protein concentation and 100 μM compound 
concentration. Spectra were recorded with 256 scans and 1.6 s mixing time at 
296 K, and by using excitation sculpting for water suppression46. Compounds 
were screened in mixtures of eight, which results in a total compound concen-
tration of 800 μM per sample. A binding hit was defined by a change-of-sign 
of the WaterLOGSY signal relative to the unbound compound.
Plasmon resonance (SPR) spectroscopy binding affinity assay. SPR experi-
ments were performed at 25 °C using a Biacore T200 instrument (GE Healthcare). 
PBS (pH 7.4) supplemented with 0.05% Tween 20 was used as running buffer. 
Human FD and FB were immobilized covalently to a Series S Sensor Chip CM5 
(GE Healthcare) at a flow rate of 10 μL/min using an amine-coupling protocol. 
Reagents for the immobilization were purchased from GE Healthcare (Amine 
Coupling Kit; BR-1000-50). The sensor-chip surface was activated by a 5 min 
injection of a 1:1 (v/v) mixture of a 100 mM N-hydroxysuccinimide (NHS) 
solution and a 390 mM 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
(EDC) hydrochloride salt solution in water. Both proteins were diluted to 
0.05 mg/mL in 20 mM HEPES pH 6.0 for immobilization onto different 
flow cells of the chip. After a 5 min injection of the protein, remaining reac-
tive groups were deactivated by injecting a 1 M ethanolamine hydrochloride 
solution in aqueous NaOH (pH 8.5) for 5 min. Different chips were used with 
immobilization levels ranging between 3,000 and 5,000 response units (RU). 
To determine kinetic parameters for the binding of compound 6 to human FD 
and FB, several independent experiments were run. Threefold serial dilutions 
of compound 6 were prepared ranging from 0.4 to 900 nM. Each solution was 
injected for 60 s at a flow rate of 30 to 60 μL/min with a dissociation time of at 
least 1,200 s (parameters identical within one experiment). Two methods were 
used to determine the kinetic parameters of the interaction: (a) standard kinet-
ics: an independent association–dissociation cycle was run for each concentra-
tion by injecting compound solution and waiting for dissociation before the 
injection of the following concentration, and (b) single cycle kinetics (SCK): 
five increasing concentrations were injected successively without allowing for 
the dissociation of the protein–ligand complex. Dissociation of the complex was 
measured once after the final compound injection. Data was fitted with Biacore 
T200 Evaluation Software using a Langmuir single-site binding model.
Computational methods: Structure-based library design based on proline 
center scaffold. The library design concept was based on the prime-site binding 
pose and key ligand–enzyme interactions observed in the crystal complex of 
compound 1 bound to human KLK7, and aimed at identifying S1 and S2′ bind-
ing motifs more specific for human FD. A virtual library of N-urea L-proline-
carboxamides was generated from a pool of 3,286 selected commercial amines 
(MW ≤350; no undesirable functional groups). Compounds were enumerated 
with Pipeline Pilot (http://accelrys.com/products/collaborative-science/biovia-
pipeline-pilot/) and then docked into the adapted 1DIC PDB crystal structure 
(1.8 Å) of human FD. This modified active site conformation was generated 
using the Maestro Protein Preparation Wizard (Schrödinger, LLC, New York, 
NY). All water molecules were removed, the protonation states were set at pH 7.4 
using Epik47, and the imidazole of the catalytic His57 residue was manually pro-
tonated (positive charge delocalized). The covalent ligand was removed and the 
torsional angle for N-Cα-Cβ-OG of the Ser195 side chain was set to X1 = 170°, 
as observed in the KLK7–inhibitor  1 crystal complex, to allow for direct 
hydrogen bond interaction of the urea carbonyl of the proline ligand with the 
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and acidified to pH 6.4 by addition of aqueous HCl solution. Serial dilutions 
of compound  6,  7, or anti-C5 eculizumab were prepared directly in acidified 
serum and were incubated on ice for 10 min. In parallel, to mimic a PNH-like 
phenotype, red blood cells (RBCs) from the same donor were masked by addi-
tion of 10 μg/mL anti-CD55 and 30 μg/mL anti-CD59 for 30 min at 37 °C with 
agitation (2 × 109 cells/mL) in HEPES-containing GVBreplacement (GVBR) 
(0.15 mM CaCl2, 145 mM NaCl, 0.1% gelatin, 4.2 mM HEPES, 5.7 mM MgCl2, 
pH 7.5). After washing in PIPES-containing GVBR (0.15 mM CaCl2, 145 mM 
NaCl, 0.1% gelatin, 10 mM PIPES, 5.7 mM MgCl2, pH 6.4), 2 × 107 masked 
RBCs per well were plated in a 96-deep-well plate containing 240 μL/well acidi-
fied serum. Erythrocytes were incubated in pure water or in 10 mM EDTA solu-
tion as controls (for maximal lysis and minimal lysis, respectively). The plate 
was sealed with a plastic adhesive film and incubated for 1 h at 37 °C with agita-
tion. To terminate the reaction, 200 μL/well of GVBR containing 15 mM EDTA 
was added and the plate was centrifuged at 4,000 r.p.m. for 5 min. Then, 100 μL 
of the supernatant was transferred into a 96-well microplate and the absorbance 
at 405 nm wavelength was measured using a SpectraMax 340PC Microplate 
Reader. The relative percentage of hemolysis was determined using the absorb-
ance in EDTA-treated serum (negative control) as baseline (i.e., 0% hemolysis) 
and the absorbance measured with the positive control (water) as maximim 
(100% hemolysis). Averages of the control quadruplets were calculated. 
%
( ) *
hemolysis
samplevalue averagebaseline
averagemaximum
=
− 100
For fluorescence-activated cell sorting (FACS) analysis of complement frag-
ments, red blood cells and supernatant of the incubated 96-deep-well plate 
were transferred into 1.5 mL Eppendorf tubes and washed with FACS buffer. 
All centrifugation steps were carried out at 11,000 r.p.m. for 5 to 7 min at 
4 °C. The antibodies anti-C3d(neo) and anti-C5b-9 were labeled with Zenon 
Labeling Kits following the manufacturer’s protocol. RBCs were incubated 
with Zenon-labeled antibodies (0.5 μg per stain) for 30 min at 4 °C in the 
dark. After staining, RBCs were washed with FACS buffer and filtered before 
FACS acquisition. Analysis was performed with an LSRFortessa Cell Analyzer 
(BD Biosciences).
IC50 values were calculated with GraphPad Prism using the equation: 
log(inhibitor) vs. response − variable slope (four parameters). The reported 
IC50 is an average of a total of 11, 2, and 7 experiments performed in duplicate 
for compounds  6,  7, and eculizumab, respectively. The FACS data was ana-
lyzed with the software FlowJo X. The debris was always gated out as much 
as possible.
Ex vivo PNH patient erythrocyte assay. Peripheral blood was collected from 
healthy volunteers (as a source for ABO-matched normal sera) and from 
PNH patients. For consistency, blood was serially drawn from the same 
three untreated patients, who exhibited a large PNH cell population (>10% 
on erythrocytes, >50% on granulocytes) for all experiments. Blood was col-
lected in standard EDTA and serum Vacutainer tubes (BD Pharmingen) after 
venipuncture according to standard procedures and following informed con-
sent as approved by the local IRB. This study was conducted in accordance 
with the Declaration of Helsinki. Erythrocytes were obtained from peripheral 
blood after three washings in saline and were subsequently incubated with 
Mg2+-supplemented sera from ABO-matched healthy individuals (NHS) at 
final hematocrits of 2%. In order to reduce inter-experiment variability, pooled 
sera from at least three subjects all with plasma C3 in the normal range were 
used. AP activation was achieved by acidification using HCl (1:20 of 0.1 N 
HCl), which resulted in a pH drop to a value between 6.7 and 6.9. Compound 
was added to the tubes at different concentrations before complement activa-
tion. After 24 h incubation time at 37 °C in acidified NHS (AcNHS), hemo-
lysis was quantified by flow cytometry after staining of the erythrocyte pellet 
with a FITC-conjugated anti-C3 polyclonal antibody (Ab14396; Abcam) and 
a PE-conjugated anti-CD59 monoclonal antibody (59-PE; Valter Occhiena). 
In brief, hemolysis was measured by comparing baseline (pre) and post-in-
cubation (post) percentage of PNH RBCs. The proportion of surviving PNH 
RBCs (% PNH post/% PNH pre) was normalized, based on the determination 
of residual normal RBCs (dividing by % N post/% N pre). The rate of hemolysis 
was then calculated as the reciprocal of the percentage of survival. This finally 
leads to the formula previously published by Ferreira et al.50: % lysis = 100 − (% 
PNH post/% N post) × (% N pre/% PNH pre) × 100.
The same anti-C3 and anti-CD59 staining also served to assess opsonization 
by evaluating the deposition of C3 fragments on erythrocytes exposed to AP 
activation in the presence of compound  7 using flow cytometry at the end of 
the hemolytic assay. The anti-C3 used in this study (Ab14396) has been shown 
to bind both C3b and its degradation fragments iC3b and C3dg49. Inhibition in 
the presence of 1 μM compound  7 was calculated by determining the average 
percent hemolysis of PNH erythrocytes at the indicated conditions for three 
individual patients (2 to 14 experiments were performed per patient). Finally, 
the individual mean result for each patient was averaged and s.e.m. was cal-
culated with GraphPad Prism and significance was determined using one-way 
analysis of variance (ANOVA) followed by Tukey’s multiple comparison test.
In vivo studies: Animals and LPS-induced complement activation.  
B6–Cfdtm1.1(CFD)Npa mice or wild type C57Bl/6 mice were maintained at Taconic 
Farms (Germantown NY, USA) and female 6-week old animals were brought 
in-house for experiments. Mice were housed in a pathogen-free facility on a 
12 h light/dark cycle. Mice were fed with standard rodent laboratory chow and 
sterile water ad libitum. Protocols, handling and care of the mice were in accord-
ance with the policy of the NIBR Cambridge Animal Care and Use Committee. 
Studies were performed in 7-week-old mice weighing approximately 20 g. 
Complement activity was induced by intraperitoneal injection of 50 μg of 
lipopolysaccharide (LPS) from Salmonella typhimurium (Sigma) dissolved 
in 100 μL sterile PBS per animal. In these studies, negative-control animals 
received an intraperitoneal injection of 100 μL sterile normal saline solution, 
and dosing vehicle alone (consisting of the formulations detailed below, minus 
the drug) by oral gavage. Positive control animals received intraperitoneal LPS 
and dosing vehicle alone by oral gavage. For compound administration, either 
a solution formulation in 20% propylene glycol and 10% solutol in water, or 
a suspension formulation using 0.5% methylcellulose and 0.5% Tween 80 in 
water, was prepared. For dose–response studies, LPS (or PBS) was adminis-
tered 7.5 h before end of study (time = 0), and compound at various doses (or 
vehicle) was administered by oral gavage 3.5 h later, or 4 h before the end of the 
study. For duration of action studies, groups of mice (grouped per time point) 
were given one dose of compound by oral gavage at 24, 16, 10, 8, 6, or 4 h before 
the end of the study (time = 0). All groups were given LPS by intraperitoneal 
injection 7.5 h before the end of the study. See Supplementary Figure 5 for a 
schematic depiction of the study designs.
Tissue collection and preparation of eye extracts. Mice were euthanized at 
indicated times. Plasma was collected in microtainer EDTA tubes (Becton 
Dickinson). Eyes without lens were collected in 2 mL microcentrifuge tubes 
(Fisher), frozen quickly on dry ice, and stored at −80 °C. Eye extracts were 
prepared by adding 200 μL of cell-lysis buffer consisting of 1× cell lysis buffer 
(Cell Signaling Technology), 1× complement mini protease inhibitor cocktail 
EDTA-free tablet (Roche Diagnostics), 1 mM PMSF (Sigma) and 20 mM PNPP 
to each sample tube. Eye tissues were then lysed with TissueLyser II (Qiagen) 
and tissue debris was pelleted by centrifugation at 11,000 r.p.m. at 4 °C for 
10 min. Supernatants were transferred to either a new tube or a 96-well plate 
and stored at −80 °C. The Bradford assay (Bradford M 1976; Pierce) was used 
to determine the protein concentration of the respective samples.
Protein gel and western blot analysis. Equal amounts of either eye protein 
extract (~40 μg protein) or 0.5 μL sampled plasma was resolved electropho-
retically on denaturing SDS polyacrylamide gels (NuPAGE 4–12% Bis–Tris gel; 
NOVEX/Invitrogen), then transferred onto nitrocellulose membranes (iBlot 
Gel Transfer Stacks Nitrocellulose; NOVEX/Invitrogen) by semi-dry blotting 
(iBlot) for 7 min. The nitrocellulose membrane was incubated with blocking 
buffer (Odyssey) for 30 min and probed overnight at 4 °C with either goat 
polyclonal anti-mouse C3d (AF2655; R & D Systems) or anti-factor B (A311; 
Quidel) primary antibody diluted by 1:2,000 in blocking buffer. The first anti-
body recognized any mouse-C3d-containing proteins, including the full-length 
C3 alpha chain (120 kDa), the C3 cleavage fragments C3b, iC3b (68 kDa), 
and C3d (41 kDa). Blots were washed three times with TBST by changing the 
buffer every 10 min and then were incubated for 1 h at room temperature with 
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the infrared fluorescently conjugated IRDye 800CW donkey anti-goat IgG 
(605-731-125; Rockland) secondary antibody diluted by 1:5,000 in blocking 
buffer. Blots were washed again as described above and infrared fluorescent 
signals were detected with an Odyssey imager (LI-COR). Fluorescent signals 
were directly proportional to the amount of the antigen on Odyssey western 
blots. The average fluorescent intensity in C3d (41 kDa) and iC3b (68 kDa) 
bands, or the Ba (33 kDa) band, assigned based on their positions relative 
to protein molecular weight markers (Bio-RAD), were quantified using 
Odyssey software.
Plasma samples (0.5 μL each) from human FD knock-in mice (B6–Cfdtm1.1(CFD)Npa 
mice) were resolved on SDS gels and transferred to nitrocellulose membranes. 
A serially diluted recombinant human FD protein (preparation described 
above) was loaded in the same gel to serve as the standard. The membranes 
were blocked using the Odyssey blocking buffer (Li-Cor) and were incubated 
with an anti-FD (AF1824; R&D) antibody overnight at 4 °C. An infrared 
fluorescently conjugated IRDye 800CW donkey anti-goat IgG (605-731-125; 
Rockland) was used as the secondary antibody to visualize the expected human 
FD protein band (~25 kDa). The fluorescent intensity of the FD protein was 
captured using Odyssey imager and software (Li-Cor). Serum FD concentra-
tion in each animal was extrapolated from the standard curve using Prism 
(GraphPad) software.
Statistical methods and in vivo data analyses. Data are presented as group 
mean ± s.e.m. Groups consisted of 4 to 10 mice as indicated. Mean differences 
were compared and considered statistically significant when P < 0.05 measured 
by one-way analysis of variance, followed by correction for multiple compari-
sons using Dunnett’s post-test, where *P < 0.05, **P < 0.01, ***P < 0.001 com-
pared to the LPS + vehicle-treated positive control group. Data was analyzed 
by subtracting the baseline values of Ba or C3d+iC3b levels measured in the 
PBS+vehicle treated groups from the respective values for each LPS treated 
group. Using the baseline-subtracted values, the percent inhibition was cal-
culated as: % inhibition = (1 – (value of Ba or C3d+iC3b in presence of LPS 
and compound) / average value of Ba or C3d+iC3b in LPS + vehicle group) 
× 100. Each type of in vivo experiment (dose–response or duration of action 
study) was conducted at least twice. Using liquid chromatography coupled to 
mass spectrometry (LC–MS), plasma levels of  6 were determined in individual 
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